By Professor Andrew David Carr

Journal articles

Sobanski MA; Barnes RA; Gray SJ; Carr AD; Kaczmarski EB; O'Rourke A; Murphy K; Cafferkey M; Ellis RW; Pidcock K; Hawtin P; Coakley WT, 2000, 'Measurement of serum antigen concentration by ultrasound-enhanced immunoassay and correlation with clinical outcome in meningococcal disease', EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 19, pp. 260 - 266, http://dx.doi.org/10.1007/s100960050473

Carr AD; Chuah J; Hudson J; French MA; Hoy JF; Law MG; Sayer D; Emery S; Cooper DA; On BOTC, 2000, 'A randomised, open-label comparison of three highly active antiretroviral therapy regimes including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study', AIDS, 14, pp. 1171 - 1180

Carr AD; Mills J; Law MG; Cooper DA, 2000, 'A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome', AIDS, 14, pp. 25 - 32

Carr AD; Cooper DA, 2000, 'Adverse effects of antiretroviral therapy', Lancet, pp. 1423 - 1430

Rhodes DI; Ashton LJ; Solomon A; Carr AD; Cooper DA; Kaldor JM; Deacon N; For TAL-T, 2000, 'Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression', Journal of Virology, pp. 10581 - 10588

Mills J; Carr AD; Smith DE; Emery S; Law MG; Grey PA; Cooper DA, 2000, 'Lipodystrophy following antiretroviral therapy of primary HIV infection (letter)', AIDS, 14, pp. 2406 - 2407

Kaufmann GR; Zaunders J; Kelleher AD; Grey PA; Smith DE; Carr AD; Cooper DA, 2000, 'Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection', AIDS, 14, pp. 2543 - 2551

Baker R; Kotler D; Carr A; Torres RA, 1999, 'Altered body shape in HIV disease: A side effect of therapy?', AIDS Patient Care and STDs, 13, pp. 395 - 402, http://dx.doi.org/10.1089/apc.1999.13.395

Cooper DA; Penny R; Symonds G; Carr AD; Gerlach W; Sun L; Ely JA, 1999, 'A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins', Human Gene Therapy, 10, pp. 1401 - 1421

Wilkinson JG; Zaunders J; Carr AD; Cooper DA, 1999, 'CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia', Journal of Infectious Diseases, 180, pp. 68 - 75

Vanhems P; Dassa C; Lambert J; Cooper DA; Perrin L; Vizzard J; Hirschel B; Kinloch-De Loes S; Carr AD; Allard R, 1999, 'Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection', Journal of acquired immune deficiency syndrome and human retrovirology, pp. 99 - 106

Carr AD; Samaras K; Thorisdottir A; Kaufmann GR; Chisholm DJ; Cooper DA, 1999, 'Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitis: a cohort study', The Lancet, pp. 2093 - 2099

Carr AD, 1999, 'HIV nucleoside analogues: new adverse effects on mitochondria', Lancet, pp. 1046 - 1047

Kaufmann GR; Cunningham PH; Zaunders J; Law MG; Vizzard J; Carr AD; Cooper DA, 1999, 'Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection', Journal of acquired immune deficiency syndrome and human retrovirology, pp. 437 - 444

Freund J; Carr A; Samaras K; Law M; Chisholm DJ; Cooper DA; Griffiths MR; Majerovic Y; Noakes KA, 1999, 'Peripheral lipodystrophy measured by DEXA in patients receiving HIV protease inhibitors', Nuclear Medicine Communications, 20, pp. 390 - 390, http://dx.doi.org/10.1097/00006231-199904000-00104

Zaunders J; Cunningham PH; Kelleher AD; Kaufmann GR; Jaramillo AB; Wright RH; Smith DE; Grey PA; Vizzard J; Carr AD; Cooper DA, 1999, 'Potent antiretroviral therapy of primary HIV-1 infection: partial normalisation of T lympho-cyte subsets and limited reduction of proviral DNA despite clearance of plasma viremia.', Journal of Infectious Diseases, 180, pp. 320 - 329

Carr AD, 1999, 'Protease inhibitor-induced lipodystrophy', AIDS Reviews, 1, pp. 29 - 36

Freund J; Griffiths MR; Majerovic Y; Noakes KA; Carr A; Cooper D, 1999, 'Skeletal display versus skeletal and soft tissue display analysis of whole-body composition', Nuclear Medicine Communications, 20, pp. 380 - 380, http://dx.doi.org/10.1097/00006231-199904000-00072

Bloch M; Carr AD; Vasak E; Cunningham PH; Smith DE, 1999, 'The use of human immunodeficiency virus post exposure prophylaxis after success-ful artificial insemination.', American Journal of Obstetrics and Gynecology, 181, pp. 760 - 761

Bloch M; Carr AD; Vasak E; Cunningham PH; Smith DD; Penny R, 1999, 'The use of human immunodeficiency virus postexposure prophylaxis following successful artificial insemination', American Journal of Obstetrics and Gynecology, 181, pp. 760 - 761

Carr A; Cooper DA, 1998, 'HIV and AIDS - Gap between biology and reality in AIDS', LANCET, 352, pp. 16 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000077742900016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Carr A; Cooper DA, 1998, 'Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor.', The New England journal of medicine, 339, pp. 1296

McAlinden MG; Magowan J; Wilson DJ; Insley G; Ferris P; Prendergast PJ; Rice J; Blayney AW; Dalstra M; Walsh M; McGloughlin T; Grace P; Colgan D; Bray D; McCormack BAO; Reilly R; Tancred D; Carr AJ; Leyland NS; Meenan J; Boyd A; Akay M; O'Dwyer B; Dunne NJ; Ryan K; Orr JF; Stungo B; Brennan EG; O'Hare NJ; Walsh MJ; Jordan MF; Rasheed AM; Kelly C; Kay E; Bouchier-Hayes DJ; Leahy A; Maher SA; O'Reilly D; Foley J; Gillan MA; Cole JS; Raghunathan S; O'Reilly MJG; Kenny T; Hourigan TF; Lyons GM; Cox SL; Kernohan WG; Fitzpatrick C; Dempsey GJ; Millar I; Kelly S; Charlwood AP; O'Brien S; Beverland DE; Kavanagh A; Neligan MF; McKenna J; Laracy P; Moran D; O'Beirne J; Nixon JR; Kenny P; Maher SA; Murphy LA; O'Rourke SK; O'Donoghue D; Gilchrist MD; Caulfield B; O'Brien B; Simms C; Lyons CG; Brady CL; Badran S; Clifford PM; Burden DJ; Taylor D; Hill R; Griffin S; De Barra E; Brook I; Reytil P; Blades M; O'Reilly JP; Masterson BF; Macauley D; Toner M; Walker J; Gillan J; Meenan J; Murphy H; McNamara P; Jones E; Kelly P; Rajah L, 1998, 'Royal academy of medicine in Ireland section of bioengineering - Proceedings of meeting held in dundalk, co. louth, in february 1998.', Irish Journal of Medical Science, 167, pp. 256 - 276, http://dx.doi.org/10.1007/BF02937426

Ryan BM; McKiernan S; Keeling PWN; Byrne PJ; Quill R; McCallion K; Mitchell RMS; Watson RGP; Collins JSA; Gardiner KR; Winter DC; O'Sullivan GC; Taylor CT; Fanning NF; Redmond HP; O'Donoghue DP; Baird AW; Harvey BJ; Brannigan AE; O'Connell PR; Regan MC; Fitzpatrick JM; Watson RWG; Lemass H; Ryan E; MacMathuna P; Crowe J; O'Keane JC; Goh J; Baird A; Maher L; Godson C; Brady HR; Petasis NA; Fokin VV; Barry MK; Grant DC; Sheahan K; O'Donoghue DP; Hyland JMP; Sheehan KM; Fitzgerald DJ; Murray FE; Heaney A; Collins JSA; Bamford KB; McFarland RJ; Tham TCK; McNamara D; Franelli S; Whelan H; Hamilton H; Beattie S; O'Morain C; Brennan EG; O'Hare N; McDermott R; Byrne PJ; McDougall NI; Collins JSA; Gieeson CM; Russell SEH; Sloan JM; Morrisey D; Murphy L; Kiely B; Fitzgerald G; Daly C; O'Sullivan G; Shanahan F; Collins JK; Marteau P; Johnston SD; Coates C; Feighery C; O'Keeffe J; Whelan A; Lynch S; Weir DG; Abuzakouk M; Barnes L; O'Gorman N; McKenna M; Freaney R; Young M; Gaines S; Brady D; Drudy D; O'Farrelly C; Gilleece A; Fenelon L; McPartlin J, 1998, 'Irish society of gastroenterology - Proceedings of meeting held Friday 12th and Saturday 13th June, 1998', Irish Journal of Medical Science, 167, pp. 2 - 22, http://dx.doi.org/10.1007/BF02937203

Wurtz R; Carr A; Samaras K; Chisholm DJ; Cooper DA; Ho TTY; Chan KCW; Wong KH; Lee SS, 1998, 'Abnormal fat distribution and use of protease inhibitors (multiple letters) [7]', Lancet, 351, pp. 1735 - 1736, http://dx.doi.org/10.1016/s0140-6736(05)77774-6

Collins S; Carr A; O'Keefe D, 1998, 'Evaluation of the effectiveness of a chronic pain management programme', Irish Journal of Psychology, 19, pp. 283 - 294, http://dx.doi.org/10.1080/03033910.1998.10558191

Carr AD; Samaras K; Burton S; Law MG; Freund J; Chisholm DJ; Cooper DA, 1998, 'A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors', AIDS, 12, pp. F51 - F58

Carr AD; Samaras K; Chisholm DJ; Cooper DA, 1998, 'Abnormal fat distribution and use of protease inhibitors', Lancet, pp. 1736 - 1736

Kelleher AD; Roggensack M; Emery S; Carr AD; French MA; Cooper DA, 1998, 'Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens', Clinical and Experimental Immunology, 113, pp. 85 - 91

Carr AD; Cooper DA, 1998, 'Gap between biology and reality in AIDS', Lancet, pp. 16 - 16

Carr AD; Cooper DA, 1998, 'Lipodystrophy associated with an HIV-protease inhibitor', New England Journal of Medicine, pp. 1296 - 1296

Carr AD; Emery S; Lloyd AR; Hoy JF; Garsia R; French MA; Stewart GA; Fyfe G; Cooper DA, 1998, 'Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, milticenter study', Journal of Infectious Diseases, 178, pp. 992 - 999, http://jid.oxfordjournals.org/content/178/4/992.full.pdf+html

Carr AD; Samaras K; Chisholm DJ; Cooper DA, 1998, 'Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance', Lancet, pp. 1881 - 1883

Kaufmann GR; Cunningham PH; Kelleher AD; Zaunders J; Carr AD; Vizzard J; Law MG; Cooper DA; Catchpole BR; Baker D; Beveridge A; Bloch M; Byrne J; Doong N; Duncombe CJ; Finlayson R; Genn W; Kidd J; Mcfarlane R; Mcmurchie M; Mcnulty A; Pethebridge A; Quan D; Robertson M, 1998, 'Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection', Journal of Infectious Diseases, 178, pp. 1812 - 1815

Wang LL; Witherington C; King AD; Gerlach W; Carr AD; Penny R; Cooper DA; Symonds G; Sun L, 1998, 'Preclinical characterization of an anti-tat ribozyme for therapeutic application', Human Gene Therapy, pp. 1283 - 1291

Ashton LJ; Carr AD; Cunningham PH; Roggensack M; Mclean K; Law MG; Robertson M; Cooper DA; Kaldor JM, 1998, 'Predictors of progression in long-term nonprogressors.', AIDS Research and Human Retroviruses, 14, pp. 117 - 121

Vanhems P; Lambert J; Cooper DA; Perrin L; Carr AD; Hirscher B; Vizzard J; Kinloch-De Loes S; Allard R, 1998, 'Severity and prognosis of acute human immunodeficiency virus type 1 illness. A dose-response relationship', Clinical Infectious Diseases, pp. 323 - 329

Carr AD; Marriott D; Field AS; Vasak E; Cooper DA, 1998, 'Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy', Lancet, pp. 256 - 261

Kaufmann GR; Duncombe CJ; Cunningham PH; Beveridge A; Carr AD; Sayer D; French MA; Cooper DA, 1998, 'Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals', AIDS, 12, pp. 1625 - 1630

Stricker RB; Goldberg B; Carr A; Cooper DA, 1997, 'CD8 T-cell response to antiretroviral therapy [1] (multiple letters)', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 15, pp. 176 - 177, http://dx.doi.org/10.1097/00042560-199706010-00015

Mitchell SM; Youle MS; Membrey WL; Jones CD; Uthayakumar S; Birthistle K; Dalton R; Hay PE; Stricker RB; Goldberg B; Carr A; Cooper DA; Stein DS; Jacobson MA, 1997, 'Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy (multiple letters) [10]', Lancet, 350, pp. 588 - 590, http://dx.doi.org/10.1016/S0140-6736(97)26034-4

Carr A, 1997, 'Role of desensitisation for drug hypersensitivity in patients with HIV infection', Drug Safety, 17, pp. 119 - 126, http://dx.doi.org/10.2165/00002018-199717020-00004

Vanhems P; Allard R; Cooper DA; Perrin L; Vizzard J; Hirschel B; Kinloch-De Loes S; Carr AD; Lambert J, 1997, 'Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive?', Clinical Infectious Diseases, pp. 965 - 970

Carr AD; Cooper DA, 1997, 'CD8 T-cell response to antiretroviral therapy', Journal of acquired immune deficiency syndrome and human retrovirology, 15, pp. 176 - 177

Carr AD; Cooper DA, 1997, 'Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy', Lancet, pp. 589 - 589

De Jong MD; Vella S; Carr AD; Boucher CA; Imrie A; French MA; Hoy JF; Sorice S; Pauluzzi S; Chiodo F; Weverling GJ; Van Der Ende ME; Frissen PJ; Weigel HM; Kauffmann RH; Lange JM; Yoon R; Moroni M; Hoenderos E; Leitz G; Cooper DA; Hall D; Reiss P, 1997, 'High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication', Journal of Infectious Diseases, 175, pp. 966 - 970

Stewart GA; Ashton LJ; Biti RA; Ffrench FA; Bennetts BH; Newcombe NR; Benson EM; Carr AD; Cooper DA; Kaldor JM; Smith DD; Catchpole BR; Allworth A; Baker D; Batty G; Beveridge A; Bloch M; Bodsworth NJ; Clare K; Cummins E; Cunningham PH; Couldwell D; Deacon N; Doong N; Finlayson R; Furner V; Huffam SE; Kidd J; Kelly MD; Lloyd AR; Mcfarlane R; Mclean K; Mcnulty A; Mcphee D; Michelmore H; Mcmurchie M; Mutimer K; Peterson J; Price R; Quan J; Qurn J; Ree H; Robertson M; Roggensack M; Schroeder K; Spencer D; Sullivan JS; Ziegler JB, 1997, 'Increased frequency of CCR-5 delta32 heterozygotes among long-term nonprogressors with HIV infection.', AIDS, 11, pp. 1833 - 1838

Carr AD; Brown DM; Cooper DA, 1997, 'Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor', AIDS, 11, pp. 1657 - 1658

Carr AD; Cooper DA, 1997, 'Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor', Lancet, pp. 995 - 996

Kelleher S; Emery S; Cunningham PH; Duncombe CJ; Carr AD; Golding H; Forde S; Hudson J; Roggensack M; Forrest BD; Cooper DA, 1997, 'Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection', AIDS Research and Human Retroviruses, 13, pp. 29 - 32

Back to profile page